Cargando…
Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
Abstract. Objective: To evaluate in healthy volunteers the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) potential of GSK2647544, (a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor). Methods: Study 1 was a single-blind, randomized, placeb...
Autores principales: | Wu, Kai, Xu, Jianfeng, Fong, Regan, Yao, Xiaozhou, Xu, Yanmei, Guiney, William, Gray, Frank, Lockhart, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299597/ https://www.ncbi.nlm.nih.gov/pubmed/27719741 http://dx.doi.org/10.5414/CP202565 |
Ejemplares similares
-
Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A(2) (Lp-PLA(2)) Inhibitor [(18)F]GSK2647544 in Healthy Male Subjects
por: Huiban, Mickael, et al.
Publicado: (2016) -
Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023) -
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014) -
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017) -
Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)